Cantor Fitzgerald downgraded Centene from Overweight to Neutral and set a new price target of $38.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/14/2025 | $33.00 | Sell | Goldman |
| 7/28/2025 | $38.00 | Overweight → Neutral | Cantor Fitzgerald |
| 7/23/2025 | $30.00 | Overweight → Equal Weight | Wells Fargo |
| 7/21/2025 | $33.00 | Buy → Hold | TD Cowen |
| 7/16/2025 | $30.00 | Neutral → Underperform | BofA Securities |
| 7/10/2025 | $33.00 | Overweight → Equal-Weight | Morgan Stanley |
| 7/2/2025 | $45.00 | Buy → Neutral | UBS |
| 7/2/2025 | $48.00 | Overweight → Neutral | Analyst |
Goldman initiated coverage of Centene with a rating of Sell and set a new price target of $33.00
Cantor Fitzgerald downgraded Centene from Overweight to Neutral and set a new price target of $38.00
Wells Fargo downgraded Centene from Overweight to Equal Weight and set a new price target of $30.00
4 - CENTENE CORP (0001071739) (Issuer)
4 - CENTENE CORP (0001071739) (Issuer)
4 - CENTENE CORP (0001071739) (Issuer)
Sessions with AcariaHealth, the National Association of Specialty Pharmacy (NASP), and Reuters Events deliver actionable insights on biosimilar adoption, patient access, and specialty pharmacy readiness ORLANDO, Fla., Nov. 20, 2025 /PRNewswire/ -- AcariaHealth, a leading specialty pharmacy and a company of Centene Corporation (NYSE: CNC), announced the completion of three national educational events in October focused on the evolving U.S. biosimilars landscape. Hosted in collaboration with NASP, Reuters Events, and through an AcariaHealth-led webinar, the sessions provided healthcare professionals with actionable, real-world guidance to support biosimilar utilization, reduce access barriers
Investment to California Association of Food Banks Will Expand Access to Nutritious Foods in Local Rural Communities SACRAMENTO, Calif., Nov. 20, 2025 /PRNewswire/ -- Health Net, one of California's most experienced Medi-Cal managed care health plans, and the Centene Foundation, the philanthropic arm of Centene Corporation (NYSE:CNC), today announced a $1.1 million investment awarded to the California Association of Food Banks to help address the growing food insecurity crisis impacting 1 in 5 Californians. Specifically, the grant will support expanding food distribution and e
Medicare Advantage plans will be available to more than 51 million beneficiaries in 32 states; Prescription Drug Plans will continue to be offered nationwide New in 2026 Wellcare to transition Medicare-Medicaid Plans (MMPs) demonstrations to integrated Dual Eligible Special Needs Plans (D-SNPs) in five states COLUMBUS, Ohio, Nov. 19, 2025 /PRNewswire/ -- Wellcare, a company offering a comprehensive range of Medicare products and the Medicare brand of Centene Corporation (NYSE: CNC), will offer Medicare Advantage (MA) to over 51 million beneficiaries in 32 states and Prescription Drug Plan (PDP) products to more than 8 million members across all 50 states. This includes 51 new counties across
8-K - CENTENE CORP (0001071739) (Filer)
SCHEDULE 13G/A - CENTENE CORP (0001071739) (Subject)
10-Q - CENTENE CORP (0001071739) (Filer)
4 - CENTENE CORP (0001071739) (Issuer)
4 - CENTENE CORP (0001071739) (Issuer)
4 - CENTENE CORP (0001071739) (Issuer)
Derrick Duke Appointed Chief Executive Officer After Transition Period Fran Soistman to Retire, Remain on eHealth Board of Directors AUSTIN, Texas, July 29, 2025 /PRNewswire/ -- eHealth, Inc. (NASDAQ:EHTH), a leading private online health insurance marketplace (the "Company"), today announced that the Company's Board of Directors has appointed Derrick Duke as its next Chief Executive Officer. Duke will join eHealth on August 4th 2025, to begin the transition process before officially stepping into the CEO role and joining the Board of Directors on September 18th, 2025. He will succeed Fran Soistman, who, as previously announced, will retire from his role as CEO while continuing to serve on t
Board further strengthened with appointment of Mike McFarland as Director National Veterinary Associates Group ("NVA"), a leading veterinary care organization, today announced it has strengthened its Board with the appointments of Ken Burdick as Executive Chairman and Dr. James "Mike" McFarland as Director. These executives bring substantial healthcare and public company experience ahead of the company's future IPO. Burdick is a seasoned public company executive with more than 40 years of healthcare experience. He currently serves as Executive Chairman at LifeStance Health (NASDAQ:LFST), a leading U.S. provider of outpatient mental healthcare. Since joining LifeStance as Chairman and CEO
ST. LOUIS, Feb. 24, 2025 /PRNewswire/ -- Centene Corporation (NYSE:CNC) ("the Company") announced today the appointment of Kenneth Y. Tanji to the Centene Board of Directors, effective February 20, 2025. Mr. Tanji will serve on the Company's Audit and Compliance Committee. The appointment of Mr. Tanji expands Centene's Board of Directors to 12 members. Mr. Tanji's finance acumen spans more than three decades and includes deep knowledge of capital optimization strategies, strategic acquisitions, JV partnership models and the use of advanced analytics and technologies to scale g
-- GAAP Diluted Loss Per Share of $(13.50); Adjusted Diluted Earnings Per Share of $0.50 -- Adjusted diluted EPS of $0.50 in the third quarter of 2025, including a $0.10 benefit of a low adjusted effective tax rate in the quarter as compared to the expected full year adjusted effective tax rate of 20-21%.$6.7 billion non-cash goodwill impairment, resulting in a GAAP loss and corresponding reduction of retained earnings in the third quarter of 2025. After the reduction to retained earnings, the debt-to-capital ratio was 45.5% at September 30, 2025.Medicaid HBR of 93.4% in the third quarter, including an approximate 40 basis point benefit from a retroactive revenue adjustment attributed to the
ST. LOUIS, Sept. 29, 2025 /PRNewswire/ -- Centene Corporation (NYSE: CNC), a leading healthcare enterprise committed to helping people live healthier lives, announced today that it will release its 2025 third quarter financial results at approximately 6:00 a.m. ET on Wednesday, October 29, 2025, and host a conference call at 9:00 a.m. ET to review the results. Investors and other interested parties are invited to listen to the conference call by dialing 1-877-883-0383 in the U.S. and Canada; +1-412-902-6506 from abroad, including the following Elite Entry Number: 0266211 to ex
-- Diluted Loss Per Share of $(0.51); Adjusted Diluted Loss Per Share of $(0.16) -- ST. LOUIS, July 25, 2025 /PRNewswire/ -- Centene Corporation (NYSE:CNC) (the Company) announced today its financial results for the second quarter ended June 30, 2025. In summary, the 2025 second quarter results were as follows: Total revenues (in millions) $ 48,742 Premium and service revenues (in millions) $ 42,467 Health benefits ratio 93.0 % SG&A expense ratio 7.1 % Adjusted SG&A expense ratio (1) 7.1 % GAAP diluted loss per share $ (0.51) Adjusted diluted loss per share (1) $ (0.16) Total cash flow provided by operations (in millions) $
SC 13G - CENTENE CORP (0001071739) (Subject)
SC 13G/A - CENTENE CORP (0001071739) (Subject)
SC 13G/A - CENTENE CORP (0001071739) (Subject)